Comment from Alliance for Regenerative Medicine

Summary: The Alliance for Regenerative Medicine (ARM), an international advocacy organization for cell and gene therapy, supports the proposed guidance but calls for greater operational clarity and specificity. They argue that the FDA should provide more objective criteria for defining "well-characterized" natural history, clarify expectations for confirmatory evidence in small populations, and better articulate how platform technologies and prior knowledge can be leveraged in CMC and clinical development.